Episode 52 -The Collective Lie in Ketamine Therapy (Part 1): Why the Experience Isn't the Treatment
Charles Miller challenges ketamine therapy's focus on psychedelic experiences, arguing that neuroplasticity science shows we're emphasizing the wrong mechanisms and reducing treatment success rates.
Audio is streamed directly from the publisher (static1.squarespace.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this first part of what became a two-part conversation, we sat down with anesthesia provider Charles Miller from Scenic City Neurotherapy for a discussion that challenged so many assumptions about ketamine therapy.
Charles presents what he calls the "collective lie" in ketamine therapy - the argument that the obsession with psychedelic experiences and mystical insights for a growing segment of providers in our industry is not just misguided, but actually making our patients worse.
He walks through the neurobiological evidence showing that the real therapeutic action happens days after treatment during the neuroplasticity window, not during those profound moments when patients feel like they're talking to God or having life-changing realizations.
You'll hear Charles critique the research methodologies that seem to support ketamine-assisted psychotherapy, explaining why group averages can mask poor individual outcomes and why the frequently cited KAP studies may actually show lower success rates than standard ketamine protocols. He also shares refreshingly honest advice about starting a clinic - including his decision to open with folding chairs rather than go into debt for impressive furniture.
We're also trying something new with this episode: audio sidebars. As we talk, we’ll pause to provide additional context about complex concepts like psychoplastogens, research study limitations, and the cutting-edge science behind separating therapeutic effects from psychedelic experiences. Think of these as educational moments designed to help you fully understand and enjoy the episode.
This conversation will make you question whether the approaches many of us have been using actually serve our patients - or if we've been chasing the wrong mechanisms entirely.
What You'll Learn in This Episode
· Charles's entrepreneurial journey - How he started Scenic City Neurotherapy with minimal capital and his advice for keeping overhead low during startup
· The "collective lie" concept - Why Charles believes the field's emphasis on ketamine experiences actually reduces treatment success rates
· Neuroplasticity mechanisms - Detailed explanation of the NMDA-glutamate-BDNF pathway and why the therapeutic window occurs after, not during, ketamine administration
· Psychoplastogens vs psychedelics - Understanding David E. Olson's groundbreaking research on compounds that promote neuroplasticity without hallucinogenic effects
· Research methodology critique - Analysis of popular KAP studies and why methodological flaws may be masking poor individual patient outcomes
· Evidence-based positioning - How to counter the "ketamine is just anesthesia" criticism with solid neurobiological science
· Experience vs neuroplasticity - Why Charles argues that focusing on insights and visions during treatment may be counterproductive
Key Takeaways
· Ketamine may function primarily as a psychoplastogen rather than a classic psychedelic, blocking NMDA receptors to trigger neuroplasticity cascades instead of flooding serotonin receptors like traditional psychedelics
· The therapeutic neuroplasticity window occur days to weeks after ketamine administration, when BDNF-driven synaptic remodeling takes place, not necessarily during the acute dissociative experience
· Research comparing ketamine-assisted psychotherapy to standard protocols could show mixed results, with some studies reporting lower individual response rates despite promising group averages
· Providers who overfocus on experiential components during treatment may inadvertently create performance pressure that could reduce patient outcomes and increase perceived treatment failure rates
· Startup ketamine clinics might benefit from beginning embarrassingly small with minimal overhead, focusing resources on essential clinical equipment rather than impressive lobbies or furniture
· David E. Olson's psychoplastogen research suggests that neuroplastic benefits might be separable from psychedelic experiences, supporting approaches that prioritize physiological mechanisms over experiential components
Episode 52 show notes:
00:00:00 - Teaser: When Patients Feel They Failed
00:00:17 - Introduction and Episode Setup
00:02:06 - Charles's Journey into Ketamine Therapy
00:04:30 - The Entrepreneurial Leap
00:06:00 - Startup Advice: Think Embarrassingly Small
00:08:30 - Evolution of the Ketamine Field
00:10:00 - The "Collective Lie" Concept Introduction
00:12:30 - Neurobiological Mechanisms
00:16:30 - Psychoplastogens vs. Psychedelics
00:24:00 - David E. Olson's Revolutionary Research
00:27:27 - Audio Sidebar: Psychoplastogens & David E. Olson
00:30:00 - Research Critique: KAP Study vs Real-World IV Ketamine Data
00:34:27 - Episode Wrap-up
Thanks for listening
📋 Professional Education Disclaimer: Content for licensed healthcare providers for educational purposes only. Does not constitute medical, legal, or business advice. Always consult qualified professionals for specific clinical and practice decisions.
Connect with Charles Miller & Scenic City Neurotherapy:
📝 Complete show notes with resources and links, please visit www.ketaminestartup.com/podcast/episode-052
Follow us on
🚀Want to fast track launching your ketamine clinic? If so, download our free checklist.